AbbVie Stock Eyes Breakout as Pipeline and Profits Grow

AbbVie (ABBV) delivered a strong Q2 2025, reporting global net revenue of $15.42 billion and EPS of $2.97, both exceeding analyst expectations, and subsequently raising its full-year EPS guidance. This performance underscores the successful diversification post-Humira patent expiration, with Skyrizi and Rinvoq revenues significantly offsetting Humira's decline. The biopharmaceutical giant is further bolstering its pipeline through strategic acquisitions, including Capstan Therapeutics and potential talks for Gilgamesh Pharmaceuticals, even as it navigates potential impacts from new EU-US pharmaceutical tariffs.

Analysis

AbbVie delivered a robust beat-and-raise for its second-quarter 2025, with global net revenue of $15.42 billion surpassing the $14.93 billion consensus and EPS of $2.97 exceeding the $2.91 forecast. This performance significantly mitigates long-standing investor concerns over the Humira patent expiration. The drug's net revenues fell 58.1% year-over-year to $1.18 billion, but this decline was more than offset by formidable growth in its next-generation immunology drugs, Skyrizi and Rinvoq, which saw revenues surge 61.8% to $4.42 billion and 41.8% to $2.02 billion respectively. This successful transition solidifies the immunology portfolio as a key growth driver, contributing nearly half of total quarterly revenue. On the back of this strength, management raised its full-year EPS guidance to a range of $11.88 to $12.08. The company is actively bolstering its pipeline through acquisitions, including the $2.1 billion deal for Capstan Therapeutics and potential acquisition of Gilgamesh Pharmaceuticals, signaling a strategic push into next-generation treatments. A notable headwind is the newly announced 15% U.S. tariff on EU-produced pharmaceuticals, which will impact key products like Botox, manufactured in Ireland. From a technical perspective, the stock is showing positive momentum, trading above its 50-day SMA and approaching a key resistance zone between $195 and $200.

Key Decisions for Investors

• Investors should view the strong performance of Skyrizi and Rinvoq as a significant de-risking event, confirming AbbVie's ability to successfully navigate the Humira patent cliff.
• Given the raised guidance, strong fundamentals, and active pipeline expansion through M&A, consider initiating or adding to positions, particularly on a sustained breakout above the $195-$200 resistance level.
• Monitor the potential margin impact from the new 15% tariff on EU-sourced pharmaceuticals as a key risk factor that could temper future earnings growth.
• For income-focused investors, the company's status as a Dividend King, with a 53-year history of increases and a current yield of 3.39%, remains a core tenet of the investment thesis.